(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 7.65% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Castle Biosciences's revenue in 2026 is $343,530,000.On average, 9 Wall Street analysts forecast CSTL's revenue for 2026 to be $9,816,437,908, with the lowest CSTL revenue forecast at $9,145,098,751, and the highest CSTL revenue forecast at $10,205,814,619. On average, 7 Wall Street analysts forecast CSTL's revenue for 2027 to be $11,143,354,346, with the lowest CSTL revenue forecast at $10,492,155,364, and the highest CSTL revenue forecast at $11,741,429,969.
In 2028, CSTL is forecast to generate $12,518,432,072 in revenue, with the lowest revenue forecast at $11,319,070,074 and the highest revenue forecast at $13,406,059,192.